Sign In
Section Navigation
Common TitleGS-141-1475
Official Title A Phase 2, Randomized, Double-Blinded Study of the Safety and Efficacy of Bictegravir (GS-9883) + Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naive Adults
Phase Phase II
ClinicalTrials.gov NCT02397694
Categories Treatment-Naive
Funding
IndustryGilead Sciences
References
  • Sax PE, DeJesus E, Crofoot G, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154-e160.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.